Abstract Number: 731 • 2012 ACR/ARHP Annual Meeting
A Systems Biology Approach to Elucidating Pathways Active During the Development of Osteoarthritis
Background/Purpose: OA affects the entire joint but most studies have focused on the disease process in a single tissue. In this study, we identified genes…Abstract Number: 732 • 2012 ACR/ARHP Annual Meeting
Changes in Subchondral Bone Provide a Sensitive Marker for Osteoarthritis and Its Progression: Results From a Large Osteoarthritis Initiative Cohort
Background/Purpose: Change in subchondral bone has been clinically associated with progression of osteoarthritis (OA). Modern image analysis techniques allow accurate, automated identification of bone in…Abstract Number: 691 • 2012 ACR/ARHP Annual Meeting
Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity
Background/Purpose: Multiple cytokines play a role in the immune dysregulation seen in systemic lupus erythematosus (SLE) and the local inflammatory responses that ultimately lead to…Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…Abstract Number: 694 • 2012 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) in the Treatment of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial
Background/Purpose: Tyrosine kinase inhibitors (TKI) which selectively antagonize c-abl and PDGFR have been shown in preclinical models to decrease fibrosis. TKIs are therapies of interest…Abstract Number: 695 • 2012 ACR/ARHP Annual Meeting
Comparison of Intense Pulsed Light and Laser Treatment of Telangiectases in Systemic Sclerosis
Background/Purpose: Cutaneous telangiectases commonly occur in systemic sclerosis (SSc) and are distressing for the patient due to their perceived unsightly appearance. The current standard treatment…Abstract Number: 696 • 2012 ACR/ARHP Annual Meeting
Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database
Background/Purpose: to identify risk factors for early mortality in a large group of recently diagnosed systemic sclerosis (SSc) patients Methods: EUSTAR collects prospectively the Minimal…Abstract Number: 697 • 2012 ACR/ARHP Annual Meeting
Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma
Multivariate Model 1 Adjusted RR 95%CI Multivariate Model 2 Adjusted RR 95%CI Male vs Female 1.4 1.1 – 1.9 Male vs Female 1,4…Abstract Number: 698 • 2012 ACR/ARHP Annual Meeting
External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients
Background/Purpose: The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is…Abstract Number: 699 • 2012 ACR/ARHP Annual Meeting
Endothelial Dysfunction and Vascular Stiffness in Early Diffuse Systemic Sclerosis
Background/Purpose: Vascular dysfunction is a hallmark of systemic sclerosis (SSc). Current theories postulate endothelial injury and dysfunction as an early event in SSc pathogenesis. Prior…Abstract Number: 700 • 2012 ACR/ARHP Annual Meeting
Clinical Correlation of Flow-Mediated Endothelium-Dependent Vasodilatation in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Evidence has…Abstract Number: 701 • 2012 ACR/ARHP Annual Meeting
Vascular Differences Associated to Genetic Polymorphisms of Endothelial Nitric Oxide Synthase in Mexican Patients with Systemic Sclerosis. A Preliminary Report
Background/Purpose: Vascular dysfunction usually is observed before clinically detectable fibrosis of systemic sclerosis (SSc). The eNOS catalyses the synthesis of nitric oxide (NO), which maintains…Abstract Number: 702 • 2012 ACR/ARHP Annual Meeting
Arterial Stiffness Is Increased in Systemic Sclerosis: A Cross-Sectional Comparison with Matched Controls
Background/Purpose: Atherosclerosis may be increased in systemic sclerosis (SSc)1. Increased arterial stiffness is a predictor of cardiovascular and all-cause mortality across a wide range of…Abstract Number: 703 • 2012 ACR/ARHP Annual Meeting
Vascular Ischemic Events in Systemic Sclerosis – A Cross-Sectional Comparision with Population-based Controls
Background/Purpose: To investigate the occurrence of ischemic vascular events and subclinical atherosclerosis in patients with systemic sclerosis (SSc) and matched population controls. Methods: 111 SSc…
ACR Meeting Abstracts